Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Cancer Related Cognitive Decline × Docetaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 44 Prostatic Neoplasms 30 Breast Neoplasms 20 Squamous Cell Carcinoma of Head and Neck 14 Lung Neoplasms 14 Stomach Neoplasms 12 Esophageal Neoplasms 12 Neoplasm Metastasis 10 Neoplasms 9 Sarcoma 7 Urinary Bladder Neoplasms 6 Ovarian Neoplasms 5 Colorectal Neoplasms 5 Carcinoma, Transitional Cell 5 Carcinoma, Renal Cell 5 Triple Negative Breast Neoplasms 4 Melanoma 4 Head and Neck Neoplasms 4 Carcinoma, Ovarian Epithelial 4 Breast Neoplasms, Male 4 Uterine Cervical Neoplasms 3 Small Cell Lung Carcinoma 3 Prostatic Neoplasms, Castration-Resistant 3 Non-Muscle Invasive Bladder Neoplasms 3 Leiomyosarcoma 3 Inflammatory Breast Neoplasms 3 Advanced Solid Tumors 3 Solid Tumors 2 Salivary Gland Neoplasms 2 Liposarcoma 2

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡